Is a 75 bps increase in interest rate on the cards?


Is a 75 bps increase in interest rate on the cards?

Ad disclosure

Invezz is an independent platform with the goal of helping users achieve financial freedom. In order to fund our work, we partner with advertisers who compensate us for users that Invezz refers to their services. While our reviews and assessments of each product on the site are independent and unbiased, brands may pay to appear higher up our table rankings or place ads in specific areas of the site. The order in which products and services appear on Invezz does not represent an endorsement from us, and please be aware that there may be other platforms available to you than the products and services that appear on our website. Read more about how we make money >


Wajeeh Khan

Apr 19, 2022

James Bullard says the U.S. central bank shouldn’t rule out a 75 bps increase in interest rate.

Wells Fargo Advisors’ Mark Smith recommends investing in “financials” in such an environment.

ERShares’ Eva Ados likes healthcare instead and is bullish on ResMed and Exelixis stocks.

An environment where rates are expected to go up rapidly warrants investing in “financials”, says Wells Fargo Advisors’ Mark Smith.

Smith’s comments on CNBC’s ‘The Exchange’

His remarks follow a further climb in the U.S. CPI to 8.5% in March that had James Bullard (President of the Federal Reserve Bank of St. Louis) suggest the central bank shouldn’t rule out a 75 bps increase in interest rate. On CNBC’s “The Exchange”, Smith said:

Are you looking for fast-news, hot-tips and market analysis?

Sign-up for the Invezz newsletter, today.

Financials is the only sector that benefits heavily from rising rates. If 75 bps as Bullard suggested comes true, financials will be the biggest beneficiary. These haven’t had huge run-ups like tech either so valuation is also great.

Bullard wants the Fed to move quickly in lifting rates to roughly 3.5% in 2022. The S&P 500 index is still down 7.0% versus the start of the year.

What to expect from U.S. equities moving forward?

ERShares’ Eva Ados doesn’t expect inflation to come down anytime soon either. She expects the U.S. equities to remain choppy this year due to the Fed tightening. On the same CNBC interview, Ados noted:

Estimates for H1 have been reassessed down. Analysts will start reassessing estimates for H2, and maybe the beginning of 2023 will also get reassessed. We’ll see another vertical shift up of the yield curve that’ll better illustrate the reality with inflation.

She sees healthcare as a suitable pick for such an environment and sees it as a space where consumers can’t cut back much on spending. Ados likes ResMed and Exelixis stocks in particular.

Invest in crypto, stocks, ETFs & more in minutes with our preferred broker,


68% of retail CFD accounts lose money

Visit site





North America

Stocks & Shares



Generated by Feedzy